Guo F, Kuo YF, Shih YCT, et al. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer 2018;124:3500–3509.
Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer 2020;126: 2225–2249.
Kaplan HG, Malmgren JA, Atwood MK, et al. Effect of treatment and mammography detection on breast cancer survival over time: 1990-2007. Cancer 2015;121:2553–2561.
Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784–1792.
Nelson HD, Fu R, Cantor A, et al. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force recommendation. Ann Intern Med 2016;164:244–255.
Plevritis SK, Munoz D, Kurian AW, et al. Association of screening and treatment with breast cancer mortality by molecular subtype in US women, 2000-2012. JAMA 2018;319:154–164.
Lobb R, Ayanian JZ, Allen JD, et al. Stage of breast cancer at diagnosis among low-income women with access to mammography. Cancer 2010;116:5487–5496.
Selvin E, Brett KM. Breast and cervical cancer screening: sociodemographic predictors among White, Black, and Hispanic women. Am J Public Health 2003;93:618–623.
Henley SJ, Thomas CC, Lewis DR, et al. Annual report to the nation on the status of cancer, part II: progress toward Healthy People 2020 objectives for 4 common cancers. Cancer 2020;126:2250–2266.
Nelson HD, Weerasinghe R, Wang L, et al. Mammography screening in a large health system following the U.S. Preventive Services Task Force recommendations and the Affordable Care Act. PLoS One 2015;10:e0131903.
U.S. Preventive Services Task Force. Final recommendation statement. Breast cancer: screening. Accessed October 27, 2020. Available at: https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening
Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 2015;314:1599–1614.
Abbott BC, Duncan EF, Grady HI, et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2018. Accessed March 15, 2018. To view the most recent version, visit NCCN.org
Lee CH, Dershaw DD, Kopans D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 2010;7:18–27.
- Search Google Scholar
- Export Citation
, Lee CH , Dershaw DD , Kopans D Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol 2010; 7: 18– 27.
Fred Hutchinson Cancer Center. Cancer surveillance system (CSS). Accessed June 23, 2020. Available at: https://www.fredhutch.org/en/research/divisions/public-health-sciences-division/research/epidemiology/cancer-surveillance-system.html
National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Accessed June 23, 2020. Available at: https://seer.cancer.gov
Miglioretti DL, Zhu W, Kerlikowske K, et al. Breast tumor prognostic characteristics and biennial vs annual mammography, age, and menopausal status. JAMA Oncol 2015;1:1069–1077.
International Classification of Diseases: Ninth Revision. Basic Tabulation List With Alphabetic Index. Geneva, Switzerland: WHO; 1978.
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.
Kind AJ, Jencks S, Brock J, et al. Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study. Ann Intern Med 2014;161:765–774.
U.S. Department of Agriculture, Economic Research Service. Documentation: 2010 Rural-Urban Commuting Area (RUCA) codes. Accessed January 19, 2020. Available at: https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes/documentation/
American Medical Association. CPT overview and code approval. Accessed June 23, 2020. Available at: https://www.ama-assn.org/practice-management/cpt/cpt-overview-and-code-approval
Centers for Medicare and Medicaid Services. HCPCS coding questions. Accessed June 23, 2020. Available at: https://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/HCPCS_Coding_Questions
Cole AP, Lu C, Krimphove MJ, et al. Comparing the association between insurance and mortality in ovarian, pancreatic, lung, colorectal, prostate, and breast cancers. J Natl Compr Canc Netw 2019;17:1049–1058.
Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008;58:9–31.
Zhang Y, Franzini L, Chan W, et al. Effects of health insurance on tumor stage, treatment, and survival in large cohorts of patients with breast and colorectal cancer. J Health Care Poor Underserved 2015;26:1336–1358.
Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. J Clin Oncol 1993;11:1936–1942.
Howlader N, Cronin KA, Kurian AW, et al. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev 2018;27:619–626.
Anderson RT, Yang TC, Matthews SA, et al. Breast cancer screening, area deprivation, and later-stage breast cancer in Appalachia: does geography matter? Health Serv Res 2014;49:546–567.
Kurani SS, McCoy RG, Lampman MA, et al. Association of neighborhood measures of social determinants of health with breast, cervical, and colorectal cancer screening rates in the US Midwest. JAMA Netw Open 2020;3:e200618.
Siu AL, U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2016;164:279–296
Qin X, Tangka FK, Guy GP Jr, et al. Mammography rates after the 2009 revision to the United States Preventive Services Task Force breast cancer screening recommendation. Cancer Causes Control 2017;28:41–48.
Wang AT, Fan J, Van Houten HK, et al. Impact of the 2009 US Preventive Services Task Force guidelines on screening mammography rates on women in their 40s. PLoS One 2014;9:e91399.
Taplin SH, Ichikawa L, Yood MU, et al. Reason for late-stage breast cancer: absence of screening or detection, or breakdown in follow-up? J Natl Cancer Inst 2004;96:1518–1527.
Rosenberg RD, Haneuse SJ, Geller BM, et al. Timeliness of follow-up after abnormal screening mammogram: variability of facilities. Radiology 2011;261:404–413.
Sprague BL, Miglioretti DL, Lee CI, et al. New mammography screening performance metrics based on the entire screening episode. Cancer 2020;126:3289–3296.
Wharam JF, Zhang F, Wallace J, et al. Vulnerable and less vulnerable women in high-deductible health plans experienced delayed breast cancer care. Health Aff (Millwood) 2019;38: 408–415.
Chlebowski RT, Kim J, Haque R. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. Cancer Prev Res (Phila) 2014;7:378–387.
Farias AJ, Du XL. Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among Medicare patients with breast cancer. J Clin Oncol 2017;35:86–95.
Sheppard VB, He J, Sutton A, et al. Adherence to adjuvant endocrine therapy in insured black and white breast cancer survivors: exploring adherence measures in patient data. J Manag Care Spec Pharm 2019;25:578–586.
Heller SL, Rosenkrantz AB, Gao Y, et al. County-level factors predicting low uptake of screening mammography. AJR Am J Roentgenol 2018;211:624–629.